Sarcoma Oncology Center, Santa Monica, California, UNITED STATES .
Surgery, USC Keck School of Medicine, Los Angeles, California, UNITED STATES .
******************************
PharmaMar, Madrid, Colmenar Viejo, SPAIN .
Massachussets General Hospital, Boston .
Hospital Universitario 12 de Octubre, Madrid, SPAIN .
Hospital Universitario Virgen del Rocio, Sevilla, SPAIN .
*******************************
*.- TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB AND TRABECTEDIN AS FIRST, SECOND/THIRD LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA, INCLUDING DESMOID TUMOR AND CHORDOMA [NCT03886311] .
Sant P. Chawla .
Sarcoma Oncology Center, Santa Monica, California, UNITED STATE
*******************************
*.- THE NITRASARC TRIAL- A NON-RANDOMIZED, OPEN-LABEL PHASE II TRIAL EVALUATING EFFICACY AND FEASIBILITY OF COMBINED TREATMENT WITH TRABECTEDIN AND NIVOLUMAB IN PATIENTS WITH METASTATIC OR INOPERABLE SOFT TISSUE SARCOMAS AFTER FAILURE OF AN ANTHRACYCLINE-CONTAINING REGIMEN :
INTERIM SAFETY ANALYSIS .
Berlin, GERMANY
******************************
*.- IMMUNE-CHECKPOINT GENES AS PREDICTIVE BIOMARKERS OF TRABECTEDIN IN ADVANCED SOFT-TISSUE SARCOMA (STS): A SPANISH GROUP FOR RESEARCH ON SARCOMAS (GEIS) TRANSLATIONAL STUDY .
Javier Martin-Broto .
Oncohematology and genetics, Institute of Biomedicine of Seville, Seville, Seville, SPAIN .
University Hospital Virgen del Rocio, Seville, SPAIN .
University Hospital Son Espases, Mallorca, SPAIN .
University Hospital Gregorio Marañon, Madrid, SPAIN .
University Hospital of Leon, Leon, SPAIN .
Hospital Clinico San Carlos, Madrid, SPAIN .
Hospital Ciudad Real, Ciudad Real, SPAIN .
Canarias University Hospital, Santa Cruz de Tenerife, SPAIN .
Vall d'Hebron University Hospital, Barcelona, SPAIN .
University Hospital Miguel Servet, Zaragoza .